ClinicalTrials.gg
CompletedNCT07169240Updated Sep 11, 2025

Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BT-114143 Injection in Healthy Subjects

A Phase 1 interventional study of BT-114143 and BT-114143 in Healthy Subjects (HS), sponsored by ScinnoHub Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-11.

Sponsored by ScinnoHub Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 6 months after the study started (first participant enrolled Feb 2023, registered Aug 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study is a single-center, randomized, double-blind, placebo-controlled, single dose escalation design to evaluate the safety, tolerability, and pharmacokinetic characteristics of BT-114143 Injection.

02

Conditions studied

  • Healthy Subjects (HS)
03

In context

Lead sponsor

ScinnoHub Pharmaceutical Co., Ltd. is the lead sponsor of 6 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects have been informed of the details of this study before the trial, have signed a written form, and voluntarily participate in the study;
  • Healthy female or male subjects aged 18-55 years (inclusive) at the time of screening;
  • Male subjects with a body weight of ≥50.0 kg and female subjects with a body weight of ≥45.0 kg; (BMI) ranging from 18.5 to 28 kg/m² (inclusive) [BMI = weight (kg) / height² (m²)];
  • No history of abnormal eye color vision, or diseases related to the heart, liver, kidney, digestive system, nervous system, mental disorders, metabolic disorders, or blood system; those whose evaluations in terms of medical history, physical examination, vital signs, chest X-ray (posteroanterior), abdominal color Doppler ultrasound, , and laboratory tests (blood routine, urine routine, blood biochemistry, coagulation function, etc.) are normal or show mild abnormalities with no clinical significance, and are deemed eligible by the researcher.

Exclusion criteria

Exclusion Criteria:

  • Confirmed as COVID-19 patients or asymptomatic infected persons upon inquiry;
  • Subjects who have undergone major surgery within 6 months prior to screening, or plan to undergo surgery during the study, as well as those who have previously undergone surgeries that may affect drug absorption, distribution, metabolism, or excretion (excluding appendectomy);
  • Subjects with a history of or persistent arterial or venous thrombosis, or at high risk of thrombosis; those with a family history of hereditary coagulation or bleeding disorders;
  • Subjects with a history of epilepsy;
  • Female subjects with a history of recurrent spontaneous abortion;
  • Subjects with positive surface antigen and/or hepatitis B e antigen, positive virus antibody, positive antibody, or positive treponema pallidum antibody;
  • Subjects with a positive alcohol breath test or positive urine drug abuse screening;
  • Heavy drinkers, i.e., consuming more than 14 standard units of alcohol per week within 3 months prior to screening (1 standard unit contains 14 g of alcohol, such as 360 mL of beer, 45 mL of spirits with 40% alcohol content, or 150 mL of wine);
  • Subjects with a history of drug abuse (e.g., morphine, tetrahydrocannabinolic acid, methamphetamine, 3,4-methylenedioxymethamphetamine, ketamine) within 1 year prior to the trial;
  • Subjects who need to take non-steroidal anti-inflammatory drugs, TXA, or blood-activating Chinese medicines (such as Panax notoginseng, Ligusticum chuanxiong, Salvia miltiorrhiza, etc.) within 1 month prior to enrollment or during the enrollment period;
  • Pregnant or lactating women, or those with positive blood pregnancy test results, as well as subjects who do not agree to take effective measures from the signing of the form until 3 months after the end of the study (see Appendix 10.1.7);
  • Subjects who participated in other clinical trials and used drugs within 3 months prior to the trial;
  • Subjects who donated blood or lost ≥400 mL of blood within 3 months prior to the trial, or plan to donate blood or have blood components drawn during the study;
  • Subjects with artificial materials in the body, such as heart valves, implants, etc., which are judged by the researcher as unsuitable for enrollment;
  • Subjects with or potential risk factors for the use of TXA, including those known to be sensitive to TXA;
  • Subjects who are judged by the researcher to have poor compliance, or have other factors that make them unsuitable for participating in this trial;
  • Subjects who cannot complete the trial for other reasons.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Dose level S-2

    Drug: BT-114143

  • Experimental
    Dose level S-1

    Drug: BT-114143

  • Experimental
    Dose level S1

    Drug: BT-114143

  • Experimental
    Dose level S2

    Drug: BT-114143

  • Experimental
    Dose level S3

    Drug: BT-114143

  • Experimental
    Dose level S4

    Drug: BT-114143

  • Experimental
    Dose level S5

    Drug: BT-114143

  • Experimental
    Dose level S6

    Drug: BT-114143

  • Experimental
    Dose level S7

    Drug: BT-114143

  • Experimental
    Dose level S8

    Drug: BT-114143

  • Experimental
    Dose level S9

    Drug: BT-114143

  • Placebo comparator
    control group

    Drug: 0.9% Sodium Chloride Injection as Placebo

Interventions

  • 6 subjects will receive a single dose of BT-114143 injection at 0.03 mg/kg.

  • 6 subjects will receive a single dose of BT-114143 injection at 0.07 mg/kg.

  • 3 subjects will receive a single dose of BT-114143 injection at 0.15 mg/kg.

  • 6 subjects will receive a single dose of BT-114143 injection at 0.3 mg/kg.

  • 6 subjects will receive a single dose of BT-114143 injection at 0.6 mg/kg.

  • 6 subjects will receive a single dose of BT-114143 injection at 1.2 mg/kg.

  • 6 subjects will receive a single dose of BT-114143 injection at 2.4 mg/kg.

  • 6 subjects will receive a single dose of BT-114143 injection at 4.8 mg/kg.

  • 6 subjects will receive a single dose of BT-114143 injection at 8.4 mg/kg.

  • 6 subjects will receive a single dose of BT-114143 injection at 12.6 mg/kg.

  • 6 subjects will receive a single dose of BT-114143 injection at 15 mg/kg.

  • Drug0.9% Sodium Chloride Injection as Placebo

    Except that the S1 dose group was a pilot study group with 1 subject matched to receive a placebo, all other dose groups were each matched with 2 subjects who received placebo treatment as controls.

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of BT-114143

    The number of Treatment-Emergent Adverse Events (TEAEs) with a severity of Grade 2 or higher in accordance with the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.

    Time frame: For single administration, the follow-up will last until Day 15 after dosing; for multiple administrations, the follow-up will last until Day 21 after dosing.

Secondary outcomes

  1. Cmax

    Maximum Concentration

    Time frame: 15 days after administration

  2. AUC

    Area Under the Concentration-Time Curve

    Time frame: 15 days after administration

  3. t1/2

    Half-Life

    Time frame: 15 days after administration

  4. CL

    Clearance

    Time frame: 15 days after administration

  5. Vz

    Volume of Distribution at Steady State

    Time frame: 15 days after administration

  6. Changes in Plasminogen Activity Results from Baseline

    Blood samples will be collected to determine the changes in plasminogen activation over time.

    Time frame: 72 hours after administration

  7. Changes in Thromboelastography (TEG) Parameters

    Blood samples will be collect at each timepoints and TEG parameter (including R, K, Angle, MA, LY30, and CI values) will be measured to determine coagulation function of each subject.

    Time frame: 72 hours after administration

  8. Prothrombin Time(PT)

    the trend of change in PT from baseline

    Time frame: 15 days after administration

  9. Activated Partial Thromboplastin Time(APTT)

    The change in Activated Partial Thromboplastin Time (APTT) from baseline

    Time frame: 15 days after administration

  10. International Normalized Ratio(INR)

    The change in INR (International Normalized Ratio) from baseline

    Time frame: 15 days after administration

  11. Fibrinogen(FIB)

    The change in FIB (Fibrinogen) from baseline

    Time frame: 15 days after administration

  12. Thrombin Time(TT)

    The change in TT (Thrombin Time) from baseline

    Time frame: 15 days after administration

  13. D-Dimer

    The change in D-Dimer (D-Dimer) from baseline

    Time frame: 15 days after administration

07

Study locations

1 site
  • PKU Care Luzhong Hospital
    Zibo, Shandong 255499, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2023 to primary completion in Apr 2024, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2025
First posted
Sep 11, 2025
StartActual
Feb 6, 2023
Primary completionActual
Apr 17, 2024
CompletionActual
Aug 2, 2025
Last update
Sep 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07169240
Lead sponsor
ScinnoHub Pharmaceutical Co., Ltd.
Collaborators
Peking University Care Luzhong Hospital
Responsible party
Sponsor
First posted
Sep 11, 2025
Start date
Feb 6, 2023
Primary completion
Apr 17, 2024
Completion
Aug 2, 2025
Last update
Sep 11, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BT-114143

Start the discussion